Search

Your search keyword '"Machherndl-Spandl, Sigrid"' showing total 27 results

Search Constraints

Start Over You searched for: Author "Machherndl-Spandl, Sigrid" Remove constraint Author: "Machherndl-Spandl, Sigrid" Publisher elsevier inc. Remove constraint Publisher: elsevier inc.
27 results on '"Machherndl-Spandl, Sigrid"'

Search Results

2. Midostaurin plus intensive chemotherapy for younger and older patients with AML and FLT3 internal tandem duplications

3. Relapse Protection Following Early Cytomegalovirus Reactivation after Hematopoietic Stem Cell Transplantation Is Limited to HLA-C Killer Cell Immunoglobulin-Like Receptor Ligand Homozygous Recipients

4. Time-dependent changes in mortality and transformation risk in MDS

5. Randomized Comparison between Krd and Ktd Induction, Followed By K Maintenance or Control in Transplant Non-Eligible Patients with NDMM: Efficacy and Qol Data (AGMT-MM02 Trial)

6. Gemtuzumab Ozogamicin Plus Intensive Chemotherapy for Patients with NPM1-Mutated Acute Myeloid Leukemia

7. Cox Proportional Hazards Deep Neural Network Identifies Peripheral Blood Complete Remission (PB-CR) to be at Least Equivalent to Morphologic CR in Predicting Outcomes of Patients Treated with Azacitidine - a Prospective Cohort Study By the AGMT

8. P-223 Pomalidomide (P) in relapsed/refractory multiple myeloma (RRMM): analysis of real-world data from an ongoing, national, multi-center, non-interventional study

9. Quality of Life in Newly Diagnosed Patients with Multiple Myeloma Randomized to Either Krd or Ktd Induction Therapy Followed By Carfilzomib Maintenance or Control (AGMT MM 02 trial)

10. Peripheral Blood Complete Remission Provides Added Value to the Classical Definition of Morphologic Complete Remission - a Prospective Cohort Study of 1441 Patients with MDS, CMML and AML Treated within the Austrian Azacitidine Registry

11. Immunophenotyping of Baseline Bone Marrow Reveals a Specific Pattern of Immune Cells Associated with Greater Depth and Sustained Response in Newly Diagnosed Patients Randomized to Krd or Ktd Followed By Carfilzomib Maintenance or Control (AGMT MM 02 Study)

12. Acute Myeloid Leukemia with Isocitrate Dehydrogenases (IDH) 1 and 2 Mutations. a Real-World Study from the European IDH Research Group

13. Expanding on Current Definitions of Hematologic Improvement in MDS, CMML and AML: Landmark Analyses of 1301 Patients Treated with Azacitidine in the Austrian Registry of Hypomethylating Agents By the AGMT-Study Group

14. Therapy-Related MDS Can be Separated into Different Risk-Groups According to Tools for Classification and Prognostication of Primary MDS

15. Real Life Experience with ATRA-Arsenic Trioxide Based Regimen in Acute Promyelocytic Leukemia - Updated Results of the Prospective German Intergroup Napoleon Registry

16. Clinical Relevance of Minimal Residual Disease Monitoring in NPM1 Mutated AML: A Study of the AML Study Group (AMLSG)

17. Clinical, Hematological, and Biologic Characteristics in Chronic Myelomonocytic Leukemia Patients with a JAK2 V617F Mutation

18. Real Life Experience with ATRA-Arsenic Trioxide Based Regimen in Acute Promyelocytic Leukemia - Updated Results of the Prospective German Intergroup Napoleon Registry

19. Intensive Post-Remission Consolidation with G-CSF-Support: Tolerability, Safety, Reduced Hospitalization, and Efficacy of a New Treatment Protocol for AML Patients ≥60 Years

20. Is It Time to Redefine Response in Elderly Patients with WHO-Acute Myeloid Leukemia (AML) Unfit for Intensive Chemotherapy?

21. Azacitidine in Acute Myeloid Leukemia with >30% Bone Marrow Blasts and

22. An Analysis of Prognostic Markers and the Performance of Scoring Systems in 1837 Patients with Therapy-Related Myelodysplastic Syndrome - a Study of the International Working Group (IWG-PM) for Myelodysplastic Syndromes (MDS)

23. Azacitidine in Acute Myeloid Leukemia: Comparison of Patients with AML-MRF Vs AML-NOS Enrolled in the Austrian Azacitidine Registry

24. Azacitidine in Patients with Acute Myeloid Leukemia: Assessing the Potential Negative Impact of Elevated Baseline White Blood Cell Count on Outcome

26. Azacitidine in Patients with Treatment-Related Acute Myeloid Leukemia: Retrospective Analysis of the Austrian Azacitidine Registry

27. Abnormal Expression Of The Major Coxsackie-Adenovirus Receptor CAR On Immature Dysplastic CD105+ Erythroid Progenitor Cells In Patients With MDS and Related Bone Marrow Neoplasms

Catalog

Books, media, physical & digital resources